Innate Pharma (IPHA) Total Liabilities (2017 - 2019)

Innate Pharma (IPHA) has 3 years of Total Liabilities data on file, last reported at $203.6 million in Q4 2019.

• For the quarter ending Q4 2019, Total Liabilities fell 37.18% year-over-year to $203.6 million; the trailing twelve-month figure through Dec 2019 stood at $203.6 million (down 37.18% YoY), and the FY2019 full-year result was $401.1 billion, up 123653.23% from the prior year.
• Total Liabilities for Q4 2019 stood at $203.6 million, down from $324.1 million in the prior quarter.
• Across five years, Total Liabilities topped out at $324.1 million in Q4 2018 and bottomed at $199.1 million in Q4 2017.
• The 3-year median for Total Liabilities is $203.6 million (2019), against an average of $242.3 million.
• The widest annual swing landed in 2018, when Total Liabilities soared 62.83%; it then tumbled 37.18% in 2019.
• A 3-year view of Total Liabilities shows it stood at $199.1 million in 2017, then jumped by 62.83% to $324.1 million in 2018, then sank by 37.18% to $203.6 million in 2019.
• The last three Total Liabilities figures came in at $203.6 million (Q4 2019), $324.1 million (Q4 2018), and $199.1 million (Q4 2017), per Business Quant data.

Peer Comparison